A Catalio-initiated liquid biopsy diagnostic company developing a best-in-class assay for the detection of minimal residual disease (MRD) to improve cancer patient outcomes. Â
Surgery remains the standard of care for most early-stage solid tumors, but most cancers recur.  Tracking progression of disease after treatment remains challenging, and it can be months or years before recurrent disease is detected by routine diagnostic work ups. Haystackâs bespoke liquid biopsy assay detects a patientâs tumor-specific markers via blood sample to identify residual disease following treatment.  The companyâs patented technology offers best-in-class sensitivity resulting in earlier detection of recurrent disease and improved outcomes for millions of cancer patients each year.â¯
Location: United States
Total raised: $56M
Investors 2
| Date | Name | Website |
| 15.11.2022 | Johns Hopk... | ventures.j... |
| - | Catalio Ca... | cataliocap... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 16.11.2022 | Series A | $56M | - |
Mentions in press and media 5
| Date | Title | Description | Source |
| 16.11.2022 | Haystack Oncology Launches with $56M for Post-Op Cancer Dete... | What You Should Know: Haystack was co-founded in 2021 by Drs. Bert Vogelstein, Ken Kinzler and Nick... | hitconsult... |
| 16.11.2022 | HLTH22 Day 3 News Summary | DispatchHealth Raises $330M for Hospital-at-Home Care DexCare Announces 50-state Project with Kaise... | hitconsult... |
| 16.11.2022 | Haystack Oncology Launches with $56M in Series A | BALTIMORE, MD, Haystack Oncology announced that it raised $56 million in Series A financing. >... | vcnewsdail... |
| 16.11.2022 | Haystack Oncology Raises $56M in Series A Funding | Haystack Oncology, a Baltimore, MD-based oncology company, raised $56M in Series A funding. The rou... | finsmes.co... |
| - | Haystack Oncology | “Make better decisions with better MRD testing Unmatched sensitivity and specificity for confident M... | fastfounde... |